163 related articles for article (PubMed ID: 10839739)
1. Potential for antimicrobial resistance in Chlamydia pneumoniae.
Stamm WE
J Infect Dis; 2000 Jun; 181 Suppl 3():S456-9. PubMed ID: 10839739
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
[TBL] [Abstract][Full Text] [Related]
3. [Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].
Zele-Starcević L; Plecko V; Budimir A; Kalenić S
Acta Med Croatica; 2004; 58(4):329-33. PubMed ID: 15700690
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
[TBL] [Abstract][Full Text] [Related]
5. Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment.
Ewald PW; Cochran GM
J Infect Dis; 2000 Jun; 181 Suppl 3():S394-401. PubMed ID: 10839723
[TBL] [Abstract][Full Text] [Related]
6. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
Hammerschlag MR; Roblin PM
J Antimicrob Chemother; 2004 Jul; 54(1):281-2. PubMed ID: 15190026
[No Abstract] [Full Text] [Related]
7. Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots.
Kumar S; Kutlin A; Roblin P; Kohlhoff S; Bodetti T; Timms P; Hammerschlag MR
J Clin Microbiol; 2007 Feb; 45(2):392-4. PubMed ID: 17122017
[TBL] [Abstract][Full Text] [Related]
8. Assay of antibiotic susceptibility of Chlamydia pneumoniae.
Hjelm E; Hultén K; Nyström-Rosander C; Gustafsson I; Engstrand L; Cars O
Scand J Infect Dis Suppl; 1997; 104():13-4. PubMed ID: 9259073
[TBL] [Abstract][Full Text] [Related]
9. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae.
Gieffers J; Rupp J; Gebert A; Solbach W; Klinger M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1402-5. PubMed ID: 15047553
[TBL] [Abstract][Full Text] [Related]
10. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
[TBL] [Abstract][Full Text] [Related]
11. Chlamydophila pneumoniae respiratory tract infection aggravates therapy refractory bronchitis or pneumonia in childhood.
Schmidt SM; Müller CE; Gürtler L; Bruns R; Ballke EH; Wiersbitzky H; Ehlers M; Rose HJ; Wiersbitzky SK
Klin Padiatr; 2005; 217(1):9-14. PubMed ID: 15640964
[TBL] [Abstract][Full Text] [Related]
12. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
[TBL] [Abstract][Full Text] [Related]
13. Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae.
Tompkins LS; Schachter J; Boman J; Chernesky MA; Dowell S; Gaydos CA; Levison ME; Maass M; Madico G; Orfila J; Ouchi K; Peeling RW; Taylor-Robinson D; Stamm WE; Wang SP; Blasi F; Relman D
J Infect Dis; 2000 Jun; 181 Suppl 3():S460-1. PubMed ID: 10839740
[No Abstract] [Full Text] [Related]
14.
Kohlhoff S; Huerta N; Hammerschlag MR
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160287
[No Abstract] [Full Text] [Related]
15. [Arteriosclerosis--a Chlamydia pneumoniae infection].
Stille W
Dtsch Med Wochenschr; 1997 Sep; 122(36):1086-91. PubMed ID: 9333533
[No Abstract] [Full Text] [Related]
16. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
17. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Hammerschlag MR; Reznik T; Roblin PM; Ramirez J; Summersgill J; Bukofzer S
J Antimicrob Chemother; 2003 Apr; 51(4):1025-8. PubMed ID: 12654764
[TBL] [Abstract][Full Text] [Related]
18. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.
Mason EO; Wald ER; Bradley JS; Barson WJ; Kaplan SL;
Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of midecamycin diacetate against Mycoplasma pneumoniae and Chlamydia pneumoniae.
Pereyre S; de Barbeyrac B; Renaudin H; Poutiers F; Bébéar C; Bébéar CM
J Antimicrob Chemother; 2001 Feb; 47(2):240-1. PubMed ID: 11157917
[No Abstract] [Full Text] [Related]
20. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
Roblin PM; Hammerschlag MR
Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
